Component

Caffeine citrate

Study-scoped entity; inspect species, exposure, model and limitations on each claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Weight gain was temporarily lower, with the greatest mean difference −23 g at two weeks.

    Caffeine citrate → Weight gain in preterm infants source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo.
    limitations
    Death, ultrasound brain-injury signs and necrotizing enterocolitis did not differ significantly in this report.
    nutrient_topic
    Caffeine collection; salts, coffee, species and coexposure contexts retain their identities. · Caffeine
    plain_language
    The benefit records retain the measured growth tradeoff.
    primary_references
    Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065

    Caffeine: receptors, metabolism, nutrient interactions, adaptation and discovery questions (2026-09-18) · lines 524–530

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. · source_derived_draft · unverified_draft

    ## caf-preterm-growth The benefit records retain the measured growth tradeoff. Weight gain was temporarily lower, with the greatest mean difference −23 g at two weeks. Model: CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. Limitations: Death, ultrasound brain-injury signs and necrotizing enterocolitis did not differ significantly in this report. Evidence access: Primary abstract Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065
    Complete structured claim and evidence

  2. At 36 weeks postmenstrual age, 36% of surviving caffeine-group infants required oxygen versus 47% with placebo; adjusted odds ratio 0.63.

    Caffeine citrate → Supplemental oxygen requirement at 36 weeks postmenstrual age source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo.
    limitations
    Specialist neonatal treatment, not dietary caffeine. Clinical outcomes do not isolate one receptor or prove benefit in other populations.
    nutrient_topic
    Caffeine collection; salts, coffee, species and coexposure contexts retain their identities. · Caffeine
    plain_language
    Clinical caffeine treatment reduced an important neonatal respiratory outcome.
    primary_references
    Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065

    Caffeine: receptors, metabolism, nutrient interactions, adaptation and discovery questions (2026-09-18) · lines 508–514

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. · source_derived_draft · unverified_draft

    ## caf-preterm-oxygen Clinical caffeine treatment reduced an important neonatal respiratory outcome. At 36 weeks postmenstrual age, 36% of surviving caffeine-group infants required oxygen versus 47% with placebo; adjusted odds ratio 0.63. Model: CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. Limitations: Specialist neonatal treatment, not dietary caffeine. Clinical outcomes do not isolate one receptor or prove benefit in other populations. Evidence access: Primary abstract Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065
    Complete structured claim and evidence

  3. Positive airway pressure ended at median 31 weeks postmenstrual age versus 32 weeks with placebo.

    Caffeine citrate → Duration of positive airway pressure in preterm infants source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo.
    limitations
    Specialist neonatal treatment, not dietary caffeine. Clinical outcomes do not isolate one receptor or prove benefit in other populations.
    nutrient_topic
    Caffeine collection; salts, coffee, species and coexposure contexts retain their identities. · Caffeine
    plain_language
    Respiratory support stopped earlier in the treatment group.
    primary_references
    Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065

    Caffeine: receptors, metabolism, nutrient interactions, adaptation and discovery questions (2026-09-18) · lines 516–522

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. · source_derived_draft · unverified_draft

    ## caf-preterm-pressure Respiratory support stopped earlier in the treatment group. Positive airway pressure ended at median 31 weeks postmenstrual age versus 32 weeks with placebo. Model: CAP randomized trial, 2006 infants weighing 500–1250 g at birth; clinical caffeine-citrate therapy versus placebo. Limitations: Specialist neonatal treatment, not dietary caffeine. Clinical outcomes do not isolate one receptor or prove benefit in other populations. Evidence access: Primary abstract Caffeine therapy for apnea of prematurity. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16707748/ · DOI 10.1056/nejmoa054065
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards